Nonadditivity in human microsomal drug metabolism revealed in a study with coumarin 152, a polyspecific cytochrome P450 substrate

References

• Brackmann U. (2000). Lambdachrome^® Laser Dyes, 3rd ed. Goettingen: Germany Lambda Physik AG.
   Google Scholar
• Brian W, Tremaine LM, Arefayene M, et al. (2016). Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG. Pharmacogenomics 17:615–31.
   PubMed Web of Science ®Google Scholar
• Chen YA, Liu LL, Khanh N, Fretland AJ. (2011). Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative extrapolation of human liver microsomal intrinsic clearance using recombinant cytochromes P450. Drug Metab Dispos 39:373–82.
   PubMed Web of Science ®Google Scholar
• Cheng YC, Prusoff WH. (1973). Relationship between the inhibition constant and the concentration of inhibitor which causes 50 percent inhibition of an enzymatic reaction. Biochem Pharmacol 22:3099–108.
   PubMed Web of Science ®Google Scholar
• Davydov DR. (2011). Microsomal monooxygenase as a multienzyme system: the role of P450-P450 interactions. Expert Opin Drug Metab Toxicol 7:543–58.
   PubMed Web of Science ®Google Scholar
• Davydov DR. (2016). Molecular organization of the microsomal oxidative system: a new connotation for an old term. Biochem Mosco 10:10–21.
   Web of Science ®Google Scholar
• Davydov DR, Davydova NY, Rodgers JT, et al. (2017). Toward a systems approach to the human cytochrome P450 ensemble: interactions between CYP2D6 and CYP2E1 and their functional consequences. Biochem J 474:3523–42.
   PubMed Web of Science ®Google Scholar
• Davydov DR, Deprez E, Hui Bon Hoa G, et al. (1995). High-pressure-induced transitions in microsomal cytochrome P450 2B4 in solution – evidence for conformational inhomogeneity in the oligomers. Arch Biochem Biophys 320:330–44.
   PubMed Web of Science ®Google Scholar
• Davydov DR, Halpert JR. (2008). Allosteric P450 mechanisms: multiple binding sites, multiple conformers or both? Expert Opin Drug Metab Toxicol 4:1523–35.
   PubMed Web of Science ®Google Scholar
• Davydov DR, Yang ZY, Davydova N, et al. (2016). Conformational mobility in cytochrome P450 3A4 explored by pressure-perturbation EPR spectroscopy. Biophys J 110:1485–98.
   PubMed Web of Science ®Google Scholar
• Davydova NY, Dangi B, Maldonado MA, et al. (2019). Toward a systems approach to cytochrome P450 ensemble: interactions of CYP2E1 with other P450 species and their impact on CYP1A2. Biochem J 476: 3661–3685.
   PubMed Web of Science ®Google Scholar
• Fang Y, Gao J, Wang T, et al. (2018a). Intraindividual variation and correlation of cytochrome P450 activities in human liver microsomes. Molecular Pharmaceutics 15:5312–8.
   PubMed Web of Science ®Google Scholar
• Fang Y, Gao N, Tian X, et al. (2018b). Effect of P450 oxidoreductase polymorphisms on the metabolic activities of ten cytochrome P450s varied by polymorphic CYP genotypes in human liver microsomes. Cell Physiol Biochem 47:1604–16.
   PubMedGoogle Scholar
• Gao N, Tian X, Fang Y, et al. (2016). Gene polymorphisms and contents of cytochrome P450s have only limited effects on metabolic activities in human liver microsomes. Eur J Pharm Sci 92:86–97.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Venkatakrishnan K, Harmatz JS, et al. (2010). Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro. Xenobiotica 40:713–20.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Zhao Y, Venkatakrishnan K, et al. (2011). Mechanism of cytochrome P450-3A inhibition by ketoconazole. J Pharm Pharmacol 63:214–21.
   PubMed Web of Science ®Google Scholar
• Halaka FG, Babcock GT, Dye JL. (1985). The use of principal component analysis to resolve the spectra and kinetics of cytochrome c oxidase reduction by 5,10-dihydro-5-methyl phenazine. Biophys J 48:209–19.
   PubMed Web of Science ®Google Scholar
• Kaspera R, Naraharisetti SB, Evangelista EA, et al. (2011). Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5. Biochem Pharmacol 82:681–91.
   PubMed Web of Science ®Google Scholar
• Korhonen LE, Turpeinen M, Rahnasto M, et al. (2007). New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis. Br J Pharmacol 150:932–42.
   PubMed Web of Science ®Google Scholar
• Krohn KA, Link JM. (2003). Interpreting enzyme and receptor kinetics: keeping it simple, but not too simple. Nucl Med Biol 30:819–26.
   PubMed Web of Science ®Google Scholar
• Kumar S. (2007). Identification of a novel laser dye substrate of mammalian cytochromes P450: application in rapid kinetic analysis, inhibitor screening, and directed evolution. J Biomol Screen 12:677–82.
   PubMedGoogle Scholar
• Lampe JN, Fernandez C, Nath A, Atkins WM. (2008). Nile red is a fluorescent allosteric substrate of cytochrome P450 3A4. Biochemistry 47:509–16.
   PubMed Web of Science ®Google Scholar
• Nad S, Kumbhakar M, Pal H. (2003). Photophysical properties of coumarin-152 and coumarin-481 dyes: unusual behavior in nonpolar and in higher polarity solvents. J Phys Chem A 107:4808–16.
   Web of Science ®Google Scholar
• Nad S, Pal H. (2001). Unusual photophysical properties of coumarin-151. J Phys Chem A 105:1097–106.
   Web of Science ®Google Scholar
• Nad S, Pal H. (2003). Photophysical properties of coumarin-500 (C500): unusual behavior in nonpolar solvents. J Phys Chem A 107:501–7.
   Web of Science ®Google Scholar
• Pelkonen O, Turpeinen M, Hakkola J, et al. (2008). Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 82:667–715.
   PubMed Web of Science ®Google Scholar
• Reed J, Backes W. (2016). The functional effects of physical interactions involving cytochromes P450: putative mechanisms of action and the extent of these effects in biological membranes. Drug Metab Rev 48:453–69.
   PubMed Web of Science ®Google Scholar
• Reed JR, Backes WL. (2017). Physical studies of P450–P450 interactions: predicting quaternary structures of P450 complexes in membranes from their X-ray crystal structures. Front Pharmacol 8:28.
   PubMed Web of Science ®Google Scholar
• Rendic S, Guengerich FP. (2010). Update Information on Drug Metabolism Systems-2009, Part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters. Curr Drug Metab 11:4–84.
   PubMed Web of Science ®Google Scholar
• Roberts AG, Yang J, Halpert JR, et al. (2011). The structural basis for homotropic and heterotropic cooperativity of midazolam metabolism by human cytochrome P450 3A4. Biochemistry 50:10804–18.
   PubMed Web of Science ®Google Scholar
• Rodrigues AD. (1999). Integrated cytochrome P450 reaction phenotyping – Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465–80.
   PubMed Web of Science ®Google Scholar
• Ryu CS, Klein K, Zanger UM. (2017). Membrane associated progesterone receptors: promiscuous proteins with pleiotropic functions – focus on interactions with cytochromes P450. Front Pharmacol 8:159.
   PubMed Web of Science ®Google Scholar
• Schoch GA, Yano JK, Sansen S, et al. (2008). Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem 283:17227–37.
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, et al. (1994). Interindividual variations in human liver cytochrome-P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic-chemicals – studies with liver-microsomes of 30 japanese and 30 caucasians. J Pharm Exp Ther 270:414–23.
   PubMed Web of Science ®Google Scholar
• Spaggiari D, Geiser L, Daali Y, Rudaz S. (2014). A cocktail approach for assessing the in vitro activity of human cytochrome P450s: an overview of current methodologies. J Pharm Biomed Anal 101:221–37.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Kneller MB, Haining RL, et al. (2002). (+)-N-3-benzyl-nirvanol and (–)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19. Drug Metab Dispos 30:235–9.
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, von Moltke LL, Court MH, et al. (2000). Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Disp 28:1493–504.
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, von Moltke LL, Greenblatt DJ. (2001). Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 41:1149–79.
   PubMed Web of Science ®Google Scholar
• Volpe DA. (2019). Interindividual variability in drug metabolizing enzymes. Curr Drug Metab 20:1041–3.
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS. (2003). Verification of the selectivity of (+)N-3-benzylnirvanol as a CYP2C19 inhibitor. Drug Metab Dispos 31:343.
   PubMed Web of Science ®Google Scholar
• Wang X, He B, Shi J, et al. (2020). Comparative proteomics analysis of human liver microsomes and S9 fractions. Drug Metab Disp 48:31–40.
   PubMed Web of Science ®Google Scholar
• Wienkers LC, Heath TG. (2005). Predicting in vivo drug interactions from in vitro drug discovery data. Nature Reviews Drug Discovery 4:825–33.
   PubMed Web of Science ®Google Scholar
• Yuan R, Madani S, Wei XX, et al. (2002). Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311–9.
   PubMed Web of Science ®Google Scholar
• Zhang WJ, Ramamoorthy Y, Kilicarslan T, et al. (2002). Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos 30:314–8.
   PubMed Web of Science ®Google Scholar
• Zhang HF, Wang HH, Gao N, et al. (2016). Physiological content and intrinsic activities of 10 cytochrome P450 isoforms in human normal liver microsomes. J Pharmacol Exp Ther 358:83–93.
   PubMed Web of Science ®Google Scholar